Zoetis to acquire Nexvet Veterinary Biologic Therapeutics Co.April 13, 2017Zoetis Inc. announced it will purchase Nexvet Biopharma veterinary biologic therapeutics company for US $6.72 per share, or a valuation of approximately US $85 million. Pending approval, the purchase is expected to be completed during the second half of 2017.
SPONSORED CONTENTManage MMVD in DogsEarly management can delay symptoms in dogs with Stage B2 MMVD. + Learn More